TRI.TO -0.02C -1.89GFL.TO 2.01BRK.B -4.78PLUS -0.79TGTX 1.01LLY -33.23SU.TO 2.79
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

30.03
-0.39 (1.28%)
as of Oct 23, 2026, 8:00:00 pm Market Closed.
585 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
DON'T BUY

Pfizer Inc(PFE)

Apr 15, 2008
US pharmaceutical sector is under tremendous pressure. Starting to see a run off in many of the product portfolios and a wind down of patent protection. With the potential change of government he expects the whole sector will be under pressure.
Photo of Alan Kral , CFA, CICAlan Kral , CFA, CIC
No
Unlock Rating
$20.71

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Apr 10, 2008
Good stock to own in a bad market. 6% yield. $25 billion in cash. The bad news is known including some of the big drugs coming off of patent and the lull before some of their late stage pipe line starts to kick in.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$20.92

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Apr 07, 2008
This is a difficult one for a value investor. The stock is down quite a bit and has a great balance sheet with a lot of cash. However, this could be a value trap. Looking forward, this company is going to be losing a lot of its primary drugs. Also, there is an election coming up and the rules may change on drug pricing.
Photo of Pat NaccaratoPat NaccaratoUnlock Rating
$21.48

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Mar 25, 2008
Dividend over 6%. Would hold for the dividend. Wouldn’t buy.
Photo of Benj GallanderBenj GallanderUnlock Rating
$20.78

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Mar 17, 2008
They’ve got lots of cash, therefore their dividend is safe. Not sure if they are going to be able to build their business to have significant growth.
Photo of David DriscollDavid Driscoll
No
Unlock Rating
$20.57

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Mar 06, 2008
Pretty cheap. Has been a dog over the last year but you are getting a 5.5% dividend. PE is 11X’s. Their patent on the Lipitor drug expires, but not for another 12 years. Cash flow from this is about 40% of their profit and they are moving into other new drugs. If the Democrats win, the question is will they get squeezed on Medicare but that is already built into the stock.
Photo of Gavin GrahamGavin Graham
Owned
Unlock Rating
$21.59

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Mar 06, 2008
Trading at 10X earnings, which is the lowest he has ever seen a US pharmaceutical. They are great beneficiaries of the lower US$. Have a great international business. Have lots of cash for acquisitions.
Photo of John ZechnerJohn Zechner
Owned
Unlock Rating
$21.59

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Mar 03, 2008
(Market Call Minute.) At this price, you can be a buyer and sell at $26 or so.
Photo of John O'Connell, CFAJohn O'Connell, CFAUnlock Rating
$22.25

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Feb 27, 2008
He has a model price of $40.10, which is a 76% positive differential. Has up its dividends considerably and has positive earnings revisions.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$22.75

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Feb 20, 2008
Their pipeline has just not produced new drugs. When you buy this stock now, you are getting a series of cash flows on the existing drugs, but a lot of them are coming off patent. Just acquired a company that has a very small drug, which to him, is a sign of desperation.
Photo of Charles BobrinskoyCharles Bobrinskoy
No
Unlock Rating
$22.47

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Feb 19, 2008
This is the worst of times for giant pharmaceutical companies. Now spending more on marketing than they are on research/development. Ongoing huge costs of developing new drugs that are safe are a drag. Also, cost of litigation remains a huge burden. Probably safer with the generic companies.
Photo of David BaskinDavid Baskin
No
Unlock Rating
$22.37

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Feb 11, 2008
Has a 2-pronged approach to the drug industry with Teva Pharmaceuticals (TEVA-Q) as his growth generic company and this one as his value dividend play. It is giving great income until their pipeline improves.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$22.20

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Feb 07, 2008
(A Top Pick Feb 1/07. Down 10% including dividends.) This one has been the bane of all value managers. His model price is $37.57, a 66% positive differential. This one needs a catalyst.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$22.67

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Jan 10, 2008
(A Top Pick Dec 18/06. Down 7.4%.) Got decimated when they lost a lawsuit on Lipitor. Sold his holdings.
Photo of David Taylor, MBA, CFADavid Taylor, MBA, CFA
No
Unlock Rating
$24.08

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jan 07, 2008
This sector does well in a slowing economy. 5.6% yield. Has a war chest of almost $30 million in cash to be used for acquisitions. Share buybacks keep increasing the dividends. Mid/long-term pipeline is very promising. Yield and cash limit downside risk. A lot of potential upside surprises.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$23.23

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
Showing 541 to 555 of 894 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

AMZN -2.38$248
META -6.23$642.62
VRT -1.27$194.32
WFC -0.62$82.39
ZS 17.39$255.15

Today's Top Picks

TRI.TO -0.02$172.41
C -1.89$120.62
GFL.TO 2.01$63.75
BRK.B -4.78$542.19
PLUS -0.79$95.36

Popular Articles

Latest Sell Signals

DOV 0$
BA 0.8$188.35
AC.TO -1.03$21.11
BB.TO 0.44$12.46
TSM 6.16$418.51

Most Recent Experts

Stephanie Link, Chief investment strategist, Hightower

Stephanie Link, Chief investment strategist, Hightower

Hightower

Jason Snipe, CIO, Odyssey Capital Advisors

Jason Snipe, CIO, Odyssey Capital Advisors

Odyssey Capital Advisors

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Tim Regan

Tim Regan

Kingwest & Company

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automatically

You may also like